Wegovy Pill vs Foundayo: What the Weekly Prescription Data Shows

The oral GLP-1 race now has a scoreboard that updates every week. In the newest edition of Fierce Pharma’s Oral GLP-1 Tracker — the edition dated Sept 11, 2026, built on IQVIA prescription data cited by Citi — Novo Nordisk’s Wegovy pill (oral semaglutide) recorded roughly 183,000 weekly prescriptions, while Eli Lilly’s Foundayo (orforglipron) recorded roughly 47,500. The gap is wide and, so far, it is holding.

What the latest edition shows

Product	Weekly prescriptions	Reporting week (as of)	Source
Wegovy pill (oral semaglutide, Novo Nordisk)	~183,000	Sept 11, 2026	Fierce Pharma Oral GLP-1 Tracker, Sept 11, 2026 edition — IQVIA data cited by Citi
Foundayo (orforglipron, Eli Lilly)	~47,500 (up nearly 8% on the week)	Sept 11, 2026	Fierce Pharma Oral GLP-1 Tracker, Sept 11, 2026 edition — IQVIA data cited by Citi
Wegovy pill (oral semaglutide, Novo Nordisk)	~181,000	Sept 4, 2026	Fierce Pharma Oral GLP-1 Tracker, Sept 4, 2026 edition — IQVIA data cited by Citi
Foundayo (orforglipron, Eli Lilly)	~44,000	Sept 4, 2026	Fierce Pharma Oral GLP-1 Tracker, Sept 4, 2026 edition — IQVIA data cited by Citi

Each row is dated because each row was read from a different edition of the same rolling page. The tracker publishes weekly updates, and a number only means something next to the edition it came from.

The trend, week by week

The Wegovy pill has held its lead without a close call. The tracker’s May 4, 2026 edition put it at roughly 135,000 weekly prescriptions. The July 24, 2026 edition put it at 169,800. The series slipped to roughly 163,000 in the Aug 14, 2026 edition. The Sept 11, 2026 edition puts it back at roughly 183,000. Four months on, the lead itself has never been close.

Foundayo is a different shape. The tracker’s first read, in the April 21, 2026 edition, recorded 1,390 weekly prescriptions. The April 24, 2026 edition recorded 3,707 — the steep early slope of a launch. The May 8, 2026 edition put it at 7,335. By the July 6, 2026 edition it was at 19,830. The Aug 28, 2026 edition reached 40,862. The Sept 11, 2026 edition puts it at roughly 47,500.

Growth is not a straight line. Foundayo read 38,928 in the Aug 14, 2026 edition. A week later, the Aug 21, 2026 edition recorded a dip to 36,620. The Aug 28, 2026 edition then set a new high at 40,862. That is why the trend matters more than any single week: one edition can wobble while the direction of travel keeps pointing up.

Which oral GLP-1 is winning?

On the Sept 11, 2026 edition of the tracker, the Wegovy pill is winning by volume: roughly 183,000 weekly prescriptions against roughly 47,500 for Foundayo, a lead of about 3.9 to 1. Both are prescription oral GLP-1s now on the market. Prescription counts measure uptake, not efficacy, and this series is not a head-to-head clinical comparison — for the trial data, dosing rules and food requirements behind both products, see our oral GLP-1 comparison, which carries the dated market-data section these figures come from.

Why a recurring tracker is the real change

Until this year, the oral GLP-1 story arrived as one-off launch announcements. Fierce Pharma’s tracker has been running since April 21, 2026, when it published its first weekly read, and it has now accumulated a continuous series. That changes what can be said. A single launch figure tells you a product exists; a dated series tells you whether a lead is widening or closing, whether a launch curve is flattening, and how fast a challenger is actually converting prescriptions.

For the two approved orals, the series so far says: the incumbent’s lead is stable in absolute terms, and the challenger is still on a launch curve.

Is the oral market growing, or taking share from injections?

This is the question a tracker can begin to address and cannot yet settle. The Sept 11, 2026 edition reports that, using the last four weeks as a guide, total GLP-1 prescriptions rose 5.4%, against a 6.8% decline in the same period a year earlier. The same edition reports Lilly’s tirzepatide holding nearly 57% of the total GLP-1 market, against around 49.5% a year earlier, with Novo’s semaglutide roughly flat at 37%.

Those are market-share and total-volume figures, not an oral-versus-injectable split. The tracker publishes totals by product, so a growing total does not by itself prove that oral GLP-1s are adding new patients rather than shifting existing ones — and a stable semaglutide share alongside a rising Wegovy pill count does not by itself prove the opposite either. Read the two together and the honest summary is that the class is growing while the orals expand; substitution inside the class remains an open question.

One caveat attaches to any direct comparison of the two counts. Citi, which cites the IQVIA data, notes that the dataset may still be missing some Foundayo prescriptions filled through telehealth channels, which makes Foundayo more likely to be understated than the Wegovy pill. The two figures are not perfectly like-for-like.

Where the numbers come from

Every figure above comes from Fierce Pharma’s weekly Oral GLP-1 Tracker, which is built on IQVIA prescription data cited by Citi. The tracker is one rolling page, which is why this article dates each figure rather than presenting a single current number. The next edition is expected Sept 18, 2026.

Our oral GLP-1 comparison page is the canonical home for this series: it carries the dated weekly-prescription table, refreshed after each edition, alongside the approved-versus-investigational status of each oral GLP-1 and the pricing and coverage picture. For the regulatory backdrop, including the split between the approved oral Wegovy pill and compounded semaglutide products, see our coverage of the compounded GLP-1 ruling.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.